Chemistry:Gadoteridol
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | (10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3−)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H29GdN4O7 |
| Molar mass | 558.69 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.[1] Gadoteridol was first approved for use in the United States in 1992.[2]
References
- ↑ Bracco Diagnostic Inc. (26 October 2022). "Gadoteridol (ProHance) prescribing information". DailyMed. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=778aee03-7d4c-481a-be8a-a75db0702f5a.
- ↑ "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology 259 (1): 109–16. April 2011. doi:10.1148/radiol.10100906. PMID 21248237. "Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.".
 |  |
